NCT00759239

Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the IOP-lowering efficacy of a combination of Travoprost / Timolol maleate, dosed in the morning or in the evening, in patients with open-angle glaucoma or ocular hypertension, who have an insufficiently controlled IOP (mmHg), and are using prostaglandin analogue monotherapy.

Conditions

• Open-angle Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Travoprost 0.004% / Timolol maleate 0.5%	Solution, morning dosing
DRUG	Travoprost 0.004% / Timolol maleate 0.5%	Solution, evening dosing

Timeline

• Start date: 2008-09-01
• Primary completion: 2011-01-01
• Completion: 2011-01-01
• First posted: 2008-09-25
• Last updated: 2016-11-22

Locations

1 site across 1 country: United Kingdom